US-based Unilife has signed a worldwide master services and commercial supply agreement with French drug-maker Sanofi for wearable injectors.
Under the 15-year deal, Unilife will supply cartridge-based wearable injectors for all of Sanofi’s applicable large dose volume drugs, excluding insulins.
The deal will also allow Sanofi to make Unilife’s wearable injectors available to its partners for use with applicable molecules under joint collaborations.
Unilife has granted Sanofi non-exclusive access to its wearable injector technology, while the French firm also has the option to extend the deal for additional periods.
In addition to upfront payment and device sales, Unilife expects to receive $50m from customisation programmes relating to Sanofi molecules and indications.
Unilife chairman and chief executive officer Alan Shortall said: "Unilife continues to advance our lead position in the fast-growing market for wearable injectors, a market which is expected to generate $8bn in sales at an average $25 per unit by 2025.
"Based upon public information and industry forecasts, Unilife estimates that Sanofi has betweenfive to ten molecules that will be delivered in wearable injectors.
"Additionally, we anticipate substantial incremental revenue will be generated from customisation programs conducted under joint collaborations with Sanofi partners that choose to participate."
The two companies will also work together to develop new technologies, which will address additional unmet or emerging needs for the delivery of large dose volume biologics.
Unilife’s Precision-Therapy platform of disposable wearable injectors can be worn on the body of a patient during the subcutaneous administration of a large dose volume drug.
The company’s wearable injectors can be prefilled, pre-assembled and ready to use, with only three intuitive steps for a patient to peel off the label, stick the product onto the body and click a button to commence the injection of a drug.